ACADIA Pharmaceuticals Inc. (ACAD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$21.48
Price Target
$34.78
Target Range
$29.00 — $40.00
Analyst Rating
Buy
Forward P/E48.5x
Trailing P/E9.4x
Forward PEG—
Implied Growth-71.0%
Median Target$35.00
Analyst Spread31.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$29
+35.0%
Consensus
$35
+61.9%
Bull Case
$40
+86.2%
ACAD Price Target Analysis
Updated May 6, 2026As of May 6, 2026, ACADIA Pharmaceuticals Inc. (ACAD) has a Wall Street consensus price target of $34.78, based on estimates from 37 covering analysts. With the stock currently trading at $21.48, this represents a potential upside of +61.9%. The company has a market capitalization of $3.68B.
Analyst price targets range from a low of $29.00 to a high of $40.00, representing a 32% spread in expectations. The median target of $35.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACAD trades at a trailing P/E of 9.4x and forward P/E of 48.5x. Analysts expect EPS to grow -71.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+32.0%
Avg Forward P/E12.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INVAInnoviva, Inc. | $1.9B | $22.52 | $37.67 | +67.3% | Buy | 11.8x | 10 |
 AXSMAxsome Therapeutics, Inc. | $11.5B | $222.63 | $225.86 | +1.5% | Buy | — | 25 |
 INTRInter & Co, Inc. | $2.5B | $7.84 | $12.00 | +53.1% | Buy | 1.9x | 6 |
 PTCTPTC Therapeutics, Inc. | $5.5B | $66.61 | $89.67 | +34.6% | Buy | — | 26 |
 BIIBBiogen Inc. | $28.2B | $190.68 | $211.42 | +10.9% | Buy | 13.0x | 48 |
 ALKSAlkermes plc | $5.9B | $35.32 | $44.00 | +24.6% | Buy | — | 28 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $51.45 | $60.00 | +16.6% | Buy | 23.7x | 14 |
 JAZZJazz Pharmaceuticals plc | $14.3B | $228.57 | $216.14 | -5.4% | Buy | 9.5x | 48 |
 NKTRNektar Therapeutics | $1.7B | $85.09 | $132.83 | +56.1% | Buy | — | 33 |
 PRAXPraxis Precision Medicines, Inc. | $7.6B | $337.95 | $544.40 | +61.1% | Buy | — | 16 |
Upside Potential Comparison
INVAPRAXNKTRINTRPTCTALKSSUPNBIIBSee ACAD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACAD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACAD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
What is the ACAD stock price target for 2026?
The consensus Wall Street price target for ACAD is $34.78, representing 61.9% upside from the current price of $21.48. With 37 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ACAD a buy, sell, or hold?
ACAD has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $34.78 implies 61.9% upside from current levels.
Is ACAD stock overvalued or undervalued?
At a forward P/E of 48.4657x, ACAD trades at a premium valuation. The consensus price target of $34.78 (61.9% upside) suggests analysts still see growth justifying the multiple.
How high can ACAD stock go?
The most bullish Wall Street analyst has a price target of $40 for ACAD, while the most conservative target is $29. The consensus of $34.78 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ACAD stock?
ACAD is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 10 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ACAD stock forecast?
The 12-month ACAD stock forecast based on 37 Wall Street analysts shows a consensus price target of $34.78, with estimates ranging from $29 (bear case) to $40 (bull case). The median consensus rating is "Buy".
What is ACAD's forward P/E ratio?
ACAD trades at a forward P/E ratio of 48.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 9.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ACAD stock?
Wall Street analysts are very optimistic on ACAD, with a "Buy" consensus rating and $34.78 price target (61.9% upside). 26 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ACAD price targets vary so much?
ACAD analyst price targets range from $29 to $40, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $34.78 consensus represents the middle ground.